|
1
|
Asa SL and Ezzat S: The pathogenesis of
pituitary tumors. Annu Rev Pathol. 4:97–126. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Osamura RY, Kajiya H, Takei M, et al:
Pathology of the human pituitary adenomas. Histochem Cell Biol.
130:495–507. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Jiang Z, Gui S and Zhang Y: Analysis of
differential gene expression by fiber-optic BeadArray and pathway
in prolactinomas. Endocrine. 38:360–368. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Jiang Z, Gui S and Zhang Y: Analysis of
differential gene expression by bead-based fiber-optic array in
growth-hormone-secreting pituitary adenomas. Exp Ther Med.
1:905–910. 2010.PubMed/NCBI
|
|
5
|
Tai HH, Cho H, Tong M and Ding Y:
NAD+-linked 15-hydroxyprostaglandin dehydrogenase:
structure and biological functions. Curr Pharm Des. 12:955–962.
2006.
|
|
6
|
Tseng-Rogenski S, Gee J, Ignatoski KW, et
al: Loss of 15-hydroxyprostaglandin dehydrogenase expression
contributes to bladder cancer progression. Am J Pathol.
176:1462–1468. 2010. View Article : Google Scholar
|
|
7
|
Liu Z, Wang X, Lu Y and Han S: Expression
of 15-PGDH is downregulated by COX-2 in gastric cancer.
Carcinogenesis. 29:1219–1227. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Lodygin D, Epanchintsev A, Menssen A,
Diebold J and Hermeking H: Functional epigenomics identifies genes
frequently silenced in prostate cancer. Cancer Res. 65:4218–4227.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Tai HH, Tong M and Ding Y:
15-hydroxyprostaglandin dehydrogenase (15-PGDH) and lung cancer.
Prostaglandins Other Lipid Mediat. 83:203–208. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Wolf I, O’Kelly J, Rubinek T, et al:
15-hydroxyprostaglandin dehydrogenase is a tumor suppressor of
human breast cancer. Cancer Res. 66:7818–7823. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Myung SJ, Rerko RM, Yan M, et al:
15-Hydroxyprostaglandin dehydrogenase is an in vivo suppressor of
colon tumorigenesis. Proc Natl Acad Sci USA. 103:12098–12102. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Wakimoto N, Wolf I, Yin D, et al:
Non-steroidal anti-inflammatory drugs suppress glioma via
15-hydroxyprostaglandin dehydrogenase. Cancer Res. 68:6978–6986.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Tai HH: Prostaglandin catabolic enzymes as
tumor suppressors. Cancer Metastasis Rev. 30:409–417. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
DeLellis RA, Lloyd RV, Heitz PU and Eng C:
Pathology and Genetics of Tumours of Endocrine Organs. WHO
Classification of Tumours. The International Agency for Research on
Cancer; Lyon: 2004
|
|
15
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kaliberova LN, Kusmartsev SA,
Krendelchtchikova V, et al: Experimental cancer therapy using
restoration of NAD+-linked 15-hydroxyprostaglandin
dehydrogenase expression. Mol Cancer Ther. 8:3130–3139. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Greenland KJ, Jantke I, Jenatschke S,
Bracken KE, Vinson C and Gellersen B: The human
NAD+-dependent 15-hydroxyprostaglandin dehydrogenase
gene promoter is controlled by Ets and activating protein-1
transcription factors and progesterone. Endocrinology. 141:581–597.
2000.
|
|
18
|
Yang L, Amann JM, Kikuchi T, et al:
Inhibition of epidermal growth factor receptor signaling elevates
15-hydroxyprostaglandin dehydrogenase in non-small cell lung
cancer. Cancer Res. 67:5587–5593. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Vidal S, Kovacs K, Bell D, Horvath E,
Scheithauer BW and Lloyd RV: Cyclooxygenase-2 expression in human
pituitary tumors. Cancer. 97:2814–2821. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Liu JK, Patel SK, Gillespie DL, Whang K
and Couldwell WT: R-flurbiprofen, a novel nonsteroidal
anti-inflammatory drug, decreases cell proliferation and induces
apoptosis in pituitary adenoma cells in vitro. J Neurooncol.
106:561–569. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Frank GR, Brar AK, Cedars MI and
Handwerger S: Prostaglandin E2 enhances human endometrial stromal
cell differentiation. Endocrinology. 134:258–263. 1994.PubMed/NCBI
|
|
22
|
Matzkin ME, Ambao V, Carino MH, et al:
Prolactin (PRL) induction of cyclooxygenase 2 (COX2) expression and
prostaglandin (PG) production in hamster Leydig cells. Mol Cell
Endocrinol. 348:33–46. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Hashizume T and Kanematsu S: Effects of
prostaglandins E2, F2α, and D2 on
the release of growth hormone, prolactin, and luteinizing hormone
from cultured bovine anterior pituitary cells. J Reprod Dev.
41:41–46. 1995.
|
|
24
|
Canete SR, Gui YH, Linask KK and Muschel
RJ: MMP-9 (gelatinase B) mRNA is expressed during mouse
neurogenesis and may be associated with vascularization. Brain Res
Dev Brain Res. 88:37–52. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Turner HE, Nagy Z, Esiri MM, Harris AL and
Wass JA: Role of matrix metalloproteinase 9 in pituitary tumor
behavior. J Clin Endocrinol Metab. 85:2931–2935. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Paez PM, Ledda MF, Goldberg V, et al: High
levels of matrix metalloproteinases regulate proliferation and
hormone secretion in pituitary cells. J Clin Endocrinol Metab.
85:263–269. 2000.PubMed/NCBI
|
|
27
|
Kulig E, Jin L, Qian X, et al: Apoptosis
in non-tumorous and neoplastic human pituitaries: expression of the
Bcl-2 family of proteins. Am J Pathol. 154:767–774. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Ozer E, Canda MS, Ulukus C, Guray M and
Erbayraktar S: Expression of Bcl-2, Bax and p53 proteins in
pituitary adenomas: an immunohistochemical study. Tumori. 89:54–59.
2003.PubMed/NCBI
|
